Monitor for actual sales execution through Form 4 filings; given BVF's size and status as a director affiliate, sustained selling could pressure the stock, especially if near-term catalysts are lacking. Consider hedging or reducing exposure if no offsetting positive developments emerge.
Price Chart
Executive Summary
BVF Partners L.P., a 10% stockholder and affiliate of a director of MoonLake Immunotherapeutics, filed a Form 144 to notify intent to sell up to 3,750,000 shares, valued at approximately $63.5 million based on the March 30, 2026 closing price. The shares were acquired in connection with the company's 2022 business combination.
Key Facts
- Reporting owner: BVF Partners L.P., a 10% stockholder and affiliate of a director
- Number of shares proposed for sale: 3,750,000
- Approximate value of shares: $63,487,500 (based on March 30, 2026 market price)
- Shares acquired: April 5, 2022, via conversion of private shares in connection with the business combination
- Filing date: March 31, 2026
- Broker-dealer of record: Goldman Sachs & Co. LLC
Financial Impact
Up to $63.5 million in potential near-term selling pressure, representing approximately 5.3% of the company's $1.2B market cap
Risk Factors
- Potential downward pressure on share price if the full amount is sold in a short period
- Signal of reduced confidence from a major shareholder and director affiliate, especially if no reinvestment or strategic rationale is disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000921895-26-000859 |
| Document: 0000921895-26-000859-index.html | 0000921895-26-000859 |
| Document: 0000921895-26-000859.txt | 0000921895-26-000859 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $17.23 | awaiting T+60 | — | $11.85 (−31.22%) |
Aug 10, 2026 11w ago | 8-K | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Aug 10, 2026 11w ago | Press Release | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Jul 20, 2026 14w ago | Insider Cluster | $19.05 $10.41 | ▲ +45.35% | ▲ +50.19% | $11.85 (+37.80%) |
Jun 25, 2026 17w ago | 8-K | $19.99 $12.39 | ▲ +38.02% | ▲ +41.87% | $11.85 (+40.72%) |
Jun 23, 2026 17w ago | Press Release | $20.00 $12.20 | ▲ +39.00% | ▲ +42.29% | $11.85 (+40.75%) |
Jun 22, 2026 18w ago | 8-K | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 21, 2026 18w ago | Press Release | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $17.75 $15.01 | ▲ +15.44% | ▲ +19.83% | $11.85 (+33.24%) |
Jun 1, 2026 21w ago | 8-K | $18.82 $15.56 | ▼ −17.32% | ▼ −18.55% | $11.85 (−37.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers